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ABSTRACT The angiotensin-converting enzyme 2 (ACE2) receptor is a major severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) host range determinant, and
understanding SARS-CoV-2-ACE2 interactions will provide important insights into
COVID-19 pathogenesis and animal model development. SARS-CoV-2 cannot infect
mice due to incompatibility between its receptor binding domain and the murine
ACE2 receptor. Through molecular modeling and empirical in vitro validation, we
identified 5 key amino acid differences between murine and human ACE2 that
mediate SARS-CoV-2 infection, generating a chimeric humanized murine ACE2.
Additionally, we examined the ability of the humanized murine ACE2 receptor to
permit infection by an additional preemergent group 2B coronavirus, WIV-1, provid-
ing evidence for the potential pan-virus capabilities of this chimeric receptor. Finally,
we predicted the ability of these determinants to inform host range identification of
preemergent coronaviruses by evaluating hot spot contacts between SARS-CoV-2
and additional potential host receptors. Our results identify residue determinants
that mediate coronavirus receptor usage and host range for application in SARS-
CoV-2 and emerging coronavirus animal model development.
IMPORTANCE SARS-CoV-2 (the causative agent of COVID-19) is a major public health
threat and one of two related coronaviruses that have caused epidemics in modern
history. A method of screening potential infectible hosts for preemergent and future
emergent coronaviruses would aid in mounting rapid response and intervention
strategies during future emergence events. Here, we evaluated determinants of
SARS-CoV-2 receptor interactions, identifying key changes that enable or prevent
infection. The analysis detailed in this study will aid in the development of model
systems to screen emergent coronaviruses as well as treatments to counteract
infections.
KEYWORDS COVID-19, SARS-CoV-2, coronavirus, host range, receptors, virus-host
interactions
Since its emergence in December 2019, severe acute respiratory syndrome coronavi-rus 2 (SARS-CoV-2) has infected tens of millions, leading to over 2 million deaths
worldwide (1, 2). SARS-CoV-2, SARS-CoV (3), and other related group 2B coronaviruses
poised for emergence (4) primarily utilize cellular angiotensin-converting enzyme 2
(ACE2) via the viral receptor binding domain (RBD) for entry. Zoonotic coronaviruses
like SARS-CoV-2 emerge following a transmission event between reservoir species and
a new permissive host where factors like RBD-receptor interactions and host proteases
support infection. Although emergent and preemergent coronaviruses have been
demonstrated to utilize ACE2 from multiple species in addition to the purported natu-
ral host, the mechanisms of these interactions are largely unknown, complicating
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OBSERVATION
reservoir species identification and disease potential in mammals. The identification
and characterization of key molecular interactions between specific RBD and ACE2
molecules could be applied to predict and determine the plasticity of the virus host
range.
In addition to providing new insights into coronavirus receptor interactions and
host range, characterizing determinants of ACE2 species restriction also has implica-
tions for SARS-CoV-2 animal model development. Mouse models have been essential
for understanding the pathogenesis of coronaviruses and have been key resources for
the preclinical development of vaccines and antiviral therapies (5–7). However, stand-
ard laboratory mice are not permissive to SARS-CoV-2 infection due to incompatible
interactions between the RBD and the mouse ACE2 receptor (mACE2) (8), which is a
substantial barrier to vaccine and antiviral development. While human ACE2 (hACE2)
mouse models (9–13) and mouse-adapted viruses (14–16) have been developed, limi-
tations exist. For example, hACE2 transgenic mice are permissive for nonadapted
SARS-CoV-2 viruses, but the pathogenesis in these mice, with mortality driven by virus-
induced encephalitis and multiorgan infection, is not representative of that observed
in humans (10, 11, 13). Additionally, mouse-adapted viruses contain amino acid
changes and do not fully reflect circulating virus strains. The development of immuno-
competent models that more faithfully model human pathogenesis will facilitate more
robust and rigorous evaluations of vaccines, antibodies, and therapeutics. To map the
SARS-CoV-2 RBD and mACE2 interaction network, we created a panel of mACE2 recep-
tors with increasing levels of humanizing mutation based on predictive structural mod-
eling, thus identifying the minimum changes necessary to restore replication.
Based on previous SARS-CoV research and published structures (17, 18), we identi-
fied likely SARS-CoV-2 RBD and ACE2 interactions via molecular modeling experiments.
The ACE2 interaction residues support the presence of three hot spots: position K353
interacts with SARS-CoV-2 binding residues G496, N501, and Y505, position K31 forms
a salt bridge with ACE2 residue K353 and interacts with SARS-CoV-2 Q493 and Y489,
and position M82 interacts with RBD residues F486, N487, and Y489 (Fig. 1a and b).
These interface hot spots are critical molecular constraints for receptor interaction and
entry, and divergent residues at these sites are predicted to significantly decrease bind-
ing between mACE2 and SARS-CoV-2 RBD (8).
In order to evaluate the impact of mACE2 humanization at each of these interaction
hot spots, we first modeled the interaction between SARS-CoV-2 RBD and mACE2
(Fig. 1c). From this, we predict that molecular incompatibility between the SARS-CoV-2
RBD and mACE2 may result in a profound loss of contact between mACE2 and the
SARS-CoV-2 RBD residues Q493 and G496. We predict this significantly contributes to
receptor incompatibility. We then modeled mutant mACE2 receptors that contain
human residues that are predicted to reestablish increasing degrees of contacts,
termed hmACE2.1 through hmACE2.4 (Fig. 1d to g) to identify and predict the changes
that would mitigate this contact loss. We predict that the single amino acid change
H353K in mACE2 can reestablish lost contacts (hmACE2.1). However, this mutation
may inappropriately remodel contact between mACE2 hot spot residue 31 and SARS-
CoV-2 RBD F456 and Y489 residues, leading to loss of function. Mutations of N31K,
S82M, and H353K in the mACE2 backbone (hmACE2.2) are predicted to reestablish the
contacts with those lost from H353K but fail to maintain contact with G496. By intro-
ducing an additional two mutations to balance charges and conformations, N30D and
F83Y (hmACE2.3), all lost contacts are predicted to be reestablished, producing a fully
humanized mACE2. Additionally in this model, SARS-CoV2 RBD-ACE2 interactions rees-
tablished by the above five amino acid changes (N30D, N31K, S82M, F83Y, and H353K)
in hmACE2.3 are the same contacts reestablished by a swap of the entire mACE2 bind-
ing interface with that of hACE2 (hmACE2.4).
To experimentally test these models, a panel of hmACE2 receptors was generated
to directly evaluate whether these predicted contact residues are essential for SARS-
CoV-2 infection. The receptors were introduced into mouse delayed brain tumor
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FIG 1 Engineered mutations in the mACE2 background reestablish contacts with SARS-CoV-2 RBD and support SARS-CoV-2 infection and replication.
(a) Residues modified to incrementally increase humanization of mACE2 (blue, mouse; pink, human). (b) Contacts between the SARS-
(Continued on next page)
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astrocytoma (DBT-9) cells (19, 20), normally nonpermissive for SARS-CoV-2 infection,
and the cells were then infected with SARS-CoV-2 to test each chimeric receptor’s abil-
ity to mediate infection. Expression of each receptor and detection of viral particles
were confirmed by Western blotting (Fig. 1h). Infection of the receptor panel by preepi-
demic SARS-like bat CoV SHC014, which does not grow in unmodified DBT cells (4, 21)
but utilizes both mACE2 and hACE2 equally, was employed as a functional positive
control (Fig. 1i). We found that all of the receptors supported SHC014 infection equiva-
lently, indicating functionally equivalent receptor surface expression. The viruses used
were derived from molecular clones that, due to the proofreading capability of the co-
ronavirus Nsp14, undergo low rates of mutation (22, 23). Consequently, our study was
designed to only sample after a single round of replication and is unlikely to amplify,
detect, or be influenced by rare variants that emerge due to binding effect. As quanti-
fied by quantitative PCR (qPCR) and viral titer, we found that all humanized receptors
supported SARS-CoV-2 entry and replication, while wild-type (WT) mACE2 did not. We
found that mACE2 facilitated isolated instances of SARS-CoV-2 entry as quantified by
luciferase assay, but the positivity is likely due to background luminescence emitted
during the assay. While a single change at position 353 was sufficient to support SARS-
CoV-2 infection by the mACE2 molecule, all five amino acid changes balancing the
three binding hot spots were required to support efficient infection at levels compara-
ble to hACE2, suggesting that satisfaction of interactions with the three hot spots are
required for maximal infection. There was no significant increase in infection of
hmACE2 remodeled to reflect the entire hACE2 binding interface past the remodeling
of the five hot spot residues (Fig. 1j to m). As such, we determined that additional
mutations past the five to satisfy the hot spots were not necessary.
Given the importance of the three ACE2 interaction hot spots for SARS-CoV-2 infec-
tion, we asked whether these same determinants were important for infection by other
preepidemic group 2B coronaviruses. We modeled interactions between hmACE2.3
and two related group 2B CoVs, preepidemic SARS-like bat CoV WIV-1 (4) and pangolin
CoV, designated P5L (Fig. 2a), a group 2B pangolin virus closely related to SARS-CoV-2
(24). Our analysis indicates that, though the RBDs of the viruses are divergent past the
hot spot-interacting residues (Fig. S3), both the P5L and WIV-1 RBD likely interact with
the three ACE2 hot spots predicted to mediate receptor binding, indicating that these
interactions may be generally important for receptor binding by SARS-CoV- and SARS-
CoV-2-like viruses (Fig. 2b to e). To further test this, we evaluated our panel of chimeric
mACE2 receptors for their ability to enhance WIV-1 murine receptor usage. Consistent
with earlier findings (4), we show that WIV-1 can utilize mACE2; however, the presence
of the 5 amino acid changes that restored the three binding hot spots significantly
increased WIV-1 infection yields to levels that were comparable to cells expressing
human ACE2 (Fig. 2f to g). Though WIV-1 replicated to higher titers in this assay than
SARS-CoV-2, there are other differences between these viruses that may result in
enhanced replication by WIV-1. Therefore, the logical interpretation is that the pres-
ence of the humanized chimeras resulted in higher rates of infection over mACE2. This
indicates that these interaction hot spots are broadly important for receptor recogni-
tion by SARS-CoV- and SARS-CoV-2-like group 2B coronaviruses and that the interac-
tions predicted are favorable for productive infection.
Recent work has identified ACE2 variants from myriad mammalian species that sup-
port SARS-CoV-2 infection (25, 26), both for model development and as potential reser-
FIG 1 Legend (Continued)
CoV-2 RBD and the three hACE2 interaction hot spots. (c) Lost contacts between mACE2 hot spots and SARS-CoV-2 RBD Q493/G496 (red). (d to g) Key
contacts gained and lost through mACE2 humanization of one amino acid change (Q493 and G496 gained, F456 and Y489 lost) (d), three amino acid
changes (Q493, F456, and Y489 maintained, G496 lost) (e), five amino acid changes (all regained) (f), and a swap of the entire hACE2 binding interface
(all maintained) (g). (h) Western blotting confirming ACE2 receptor expression (anti-6-His) and SARS-CoV-2 (anti-nucleocapsid) infection. (i) qPCR 24 h
after infection by SARS-like virus SHC014. (j) qPCR. (k) Genome equivalents. (l) Luciferase. (m) Titer 24 h following virus infection. n= 3 replicates per
sample. Data analyzed by 2-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons. Error bars represent standard error about
the mean. *, comparisons to mock where P# 0.0001; x, comparisons to mock where P# 0.001; 1, comparisons to mACE2 where P# 0.0001. sgRNA,
single guide RNA.
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voirs. Though ACE2 variant sequences are divergent, we asked whether the sequence
homology was sufficient to model the interactions between these host receptors and
the SARS-CoV-2 RBD. Based on pairwise sequence alignments to hACE2 (Fig. S2), we
modeled the RBD interaction with ACE2 molecules from species reported to support
entry and infection in vitro (ferret, macaque, mink, cat, pig, guinea pig, and dog) as
well as those from species reported to support little to no infection (mouse, chicken)
(Fig. S1) (25, 27). The molecular interactions, both favorable and unfavorable, we pre-
dicted align with the differences in infection identified in recent work. For example,
though human and ferret ACE2 differ at residue 81, we predict the SARS-CoV-2 RBD
still interacts favorably with ferret ACE2 to satisfy the three critical interaction hot
spots. Conversely, though chicken ACE2 contains hot spot residue K353, we predict
molecular incompatibility due to lack of contact at hot spot 31. Furthermore, ACE2
molecules from other highly susceptible species are homologous in some (cats) or all
FIG 2 hmACE2 contacts with WIV-1 and P5L are predicted to support replication. (a) Aligned contact residues of SARS-CoV-2, SARS-CoV, WIV-1, and P5L. (b
and c) Contacts identified between mACE2 and WIV-1 (b) and those gained between hmACE2 and WIV-1 (c) include Y482 and D481. (d and e) Contacts
identified between mACE2 and P5L (d) and gained between hmACE2 and P5L (e) include G496, E493, and F456 (right). (f and g) qPCR (f) and titer (g) 24 h
following WIV-1 infection. Data analyzed by 2-way ANOVA followed by Dunnett’s multiple comparisons. Error bars represent standard error about the
mean. *, comparisons to mock where P# 0.0001. Plus signs represent comparisons to mACE2 (1, P# 0.05; 11, P# 0.01; 111, P# 0.001; 1111,
P# 0.0001).
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(nonhuman primates) hot spot residues, which enable contact between the three hot
spots and the SARS-COV-2 RBD (8), providing further support that the hot spot analysis
is highly informative. Our predictions indicate that the three hot spots may be used to
accurately predict the receptor interaction between ACE2 and group 2B coronaviruses
and that the sequence homology between ACE2 molecules is sufficient to model these
interactions in instances where no experimentally determined structure is available.
This enables a molecular modeling-based screening approach to host range predic-
tions. Furthermore, while additional work has found that some animals predicted to be
reservoirs to SARS-CoV-2 infection are not permissive in vivo (27, 28), all of the animals
predicted to not be infectible based on receptor interaction have been identified as
nonpermissive hosts. This shows that, while favorable receptor interaction may not be
sufficient for productive infection, it is a primary determinant of host range.
Additionally, this work demonstrates that this contact analysis can be used to rapidly
filter ACE2 molecules from different species to identify or eliminate potential reservoir
hosts or animal models.
Our results provide key insights into the amino acid differences between human
and mouse ACE2 molecules that are responsible for determining SARS-CoV-2 recep-
tor activity and species specificity. In mouse-adapted viruses, mACE2 binding was
restored by the single mutations Q498H (29), N501Y (16), Q498Y (14), and Q493K
(15), demonstrating several pathways to increased mACE2 usage. Recent work has
also identified various isolates able to infect mink that contain RBD substitution
Y453F, which likely improves contact with hot spot 31 in the mink ACE2 molecule
and appear to retain contact with all hot spots in human ACE2 (30). Furthermore,
emerging variants from Africa and London contain substitution N501Y, an RBD sub-
stitution that likely improves contact with both mouse ACE2 and human ACE2, due
to biochemical and structural property changes at hot spot 353. These data (supple-
mental material) support our findings that interactions at single hot spots enhance
usage, leading to multiple evolutionary pathways to adaptation, but efficient adap-
tation may require multiple mutations that allow for efficient usage of multiple hot
spots. We also identified key contact residues within ACE2 that mediate receptor
interactions with other epidemic and preepidemic group 2B coronaviruses. Given
the importance of these interactions for SARS-CoV-2 infection, we suggest that
these determinants may be used to also predict susceptible species for model de-
velopment or reservoir formation. Furthermore, it should be possible to introduce
these changes into the mACE2 gene in vivo by gene editing (31), thereby generat-
ing a chimeric ACE2 receptor with physiologic expression patterns that is capable
of mediating infection by clinical isolates of SARS-CoV-2 and potentially preemer-
gent group 2B coronaviruses. This work did not address, however, the influence of
ACE2 isoforms or allelic variants on host susceptibility, including cytokine-inducible
ACE2 variants or variation in ACE2 expression levels (32, 33). In addition to isoform
expression, host factors like protease state also significantly impact cellular suscep-
tibility to SARS-CoV-2 (34, 35), as evidenced by conflicting results between in vitro
assays and in vivo infection to identify potential SARS-CoV-2 reservoir species and
animal models (25, 26, 28). We have found that favorable receptor interaction is
absolutely necessary for productive infection, consonant with earlier findings (36),
but all potential hosts must be fully evaluated in downstream analysis to investi-
gate additional factors determining host range.
Molecular modeling and visualization. The ACE2 panel was aligned using
Geneious Prime (version 2020.0.5). The hACE2 sequence is found under GenBank
accession no. BAB40370 and mACE2 sequence under GenPept accession no. NP
_081562. Scores were computed using BLOSUM62 scoring matrix. Three-dimensional
structures were predicted using MODELLER homology modeling tool (37) from pairwise
sequence alignment to the reference SARS-CoV-2 RBD hACE2 complex (PDB ID 6M0J)
and SARS-CoV RBD hACE2 complex (PDB ID 2AJF). WIV-1 RBD was modeled using the
reference sequence, GenPept accession no. AGZ48828.1, and P5L RBD was modeled
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using GenBank accession no. MT040335.1. Additional receptor interactions were
modeled from the following translated reference sequences: chicken, GenBank accession
no. XM_416822.5; guinea pig, GenBank accession no. XM_023562040.1; ferret, GenBank
accession no. XM_004758886.2; pig, GenBank accession no. EU518378.1; dog, GenBank
accession no. NM_001165260.1; macaque, GenBank accession no. NM_001135696.1; and
mink, GenBank accession no. MT560518.1. Contacts were identified and visualized in the
PyMOL molecular graphics system (Schrödinger LLC). Structure-based multiple sequence
alignment was generated with UCSF Chimera.
Viruses and cells. All viruses were derived using infectious clone technology as pre-
viously described, including icSARS-CoV-2-WT (GenBank accession no. MT461669),
icSARS-CoV-2-nLuc (GenBank accession no. MT461671) (38), and icWIV1-CoV (4)
(GenBank accession no. KF367457.1). Mouse delayed brain tumor astrocytoma (DBT-9)
(19, 20) cells were maintained in minimum essential medium (MEM; Gibco), 10% fetal
clone II serum (FCII; HyClone), and 1 antibiotic/antimycotic (Gibco). Vero E6 cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco), 5% FC11, and
1 antibiotic/antimycotic.
ACE2 panel construction. Each mouse, human, and chimeric ACE2 was expressed
in pCDNA3.1 vector that conjugates a C-terminal 6-His tag to the end of the
expressed protein. The hmACE2 panel was generated with a combination of site-
directed mutagenesis and custom double-stranded gBlocks gene fragments (IDT). DBT-
9 cells were transfected using Lipofectamine 2000 transfection reagent (Invitrogen).
Expression of each receptor was verified via staining against a 6-His epitope
(Invitrogen; catalog no. PA1-983B) and Western blotting.
Infection and analysis. Cells were infected in triplicate 24 h posttransfection for re-
ceptor usage analysis at a multiplicity of infection (MOI) of 1 for 1 h. Inoculum was
removed, cells were washed with Dulbecco's phosphate-buffered saline (DPBS), and
medium was replaced. Receptor usage was analyzed 24 h postinfection. RNA was col-
lected via TRIzol (Invitrogen) and extracted using Direct-zol RNA MiniPrep kit (Zymo
Research). Viral RNA was quantified in duplicate via reverse transcriptase quantitative
PCR (qRT-PCR) using TaqMan Fast Virus 1-Step Master Mix (Thermo Fisher Scientific) on
a QuantStudio 3 (Applied Biosystems). Viral RNA was quantified with a subgenomic
diagnostic assay primer set (Table 1). Host 18S rRNA was used as housekeeping control
(Invitrogen; catalog no. 4319413E). Viral RNA was analyzed using the threshold cycle
(DDCT) method and fold change over viral RNA in empty vector-transfected cells.
SARS-CoV-2 genome equivalents were calculated against a standard curve with a diag-
nostic genomic assay primer set against Nsp4 (Table 1). Receptor expression was con-
firmed via Western blotting against the 6-His tag and virus nucleocapsid. For virus ti-
ter calculation, Vero E6 cells were infected at an MOI of 1 for 1 h. Inoculum was
removed, and the monolayer was washed with PBS and replaced with medium. The
medium was removed 24 h postinfection and stored at 280°C until the titer was deter-
mined by plaque assay. Briefly, virus was serial diluted and inoculated onto confluent
monolayers of Vero E6 cells, followed by agarose overlay. Plaques were visualized on
day 2 postinfection via staining with neutral red dye.
TABLE 1 Primers and sequences used in this study
Primer Sequence
SARS-CoV-2 sgN F 59-TTCGATCTCTTGTAGATCTGTTCTC-39
SARS-CoV-2 sgN R 59-GCGTTCTCCATTCTGGTTACT-39
SARS-CoV-2 sgN probe 59-FAM-ACGTTTGGTGGACCCTCAGATTCA-39
SARS-CoV-2 Nsp4 F 59-GTGCTCATGGATGGCTCTATTA-39
SARS-CoV-2 Nsp4 R 59-CGTGCCTACAGTACTCAGAATC-39
SARS-CoV-2 Nsp4 probe 59-FAM-ACCTACCTTGAAGGTTCTGTTAGAGTGGT-39
WIV1-CoV sgN F 59-CGATCTCTTGTAGATCTGTTCTCTAA-39
WIV1-CoV sgN R 59-CTGTGGGTCCACCAAATGTA-39
WIV1-CoV sgN probe 59-FAM-CCAATCAAACCAGCGTAGTGCCC-39
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Data availability. All relevant data sets generated or analyzed in this study have
been included in the article. Additional information, including replicates, is available
upon request.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
FIG S1, TIF file, 1.1 MB.
FIG S2, TIF file, 0.7 MB.
FIG S3, TIF file, 1.5 MB.
ACKNOWLEDGMENTS
This project was funded in part by the National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Department of Health and Human Service
awards 1R01 AI089728, U54 CA260543, and 1R01 AI110700. This project was supported
in part by the North Carolina Policy Collaboratory at the University of North Carolina at
Chapel Hill with funding from the North Carolina Coronavirus Relief Fund established
and appropriated by the North Carolina General Assembly.
REFERENCES
1. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H,
Pei Y-Y, Yuan M-L, Zhang Y-L, Dai F-H, Liu Y, Wang Q-M, Zheng J-J, Xu L,
Holmes EC, Zhang Y-Z. 2020. A new coronavirus associated with human
respiratory disease in China. Nature 579:265–269. https://doi.org/10
.1038/s41586-020-2008-3.
2. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B,
Huang C-L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y,
Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B,
Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. 2020. A pneumonia outbreak asso-
ciated with a new coronavirus of probable bat origin. Nature 579:
270–273. https://doi.org/10.1038/s41586-020-2012-7.
3. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. 2020. The proxi-
mal origin of SARS-CoV-2. Nat Med 26:450–452. https://doi.org/10.1038/
s41591-020-0820-9.
4. Menachery VD, Yount BL, Sims AC, Debbink K, Agnihothram SS, Gralinski
LE, Graham RL, Scobey T, Plante JA, Royal SR, Swanstrom J, Sheahan TP,
Pickles RJ, Corti D, Randell SH, Lanzavecchia A, Marasco WA, Baric RS.
2016. SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad
Sci U S A 113:3048–3053. https://doi.org/10.1073/pnas.1517719113.
5. Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist
SR, Schäfer A, Dinnon KH, Stevens LJ, Chappell JD, Lu X, Hughes TM,
George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus
MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A,
Thornburg NJ, Swanstrom R, Denison MR, Baric RS. 2020. An orally bioa-
vailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway
epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med
12:eabb5883. https://doi.org/10.1126/scitranslmed.abb5883.
6. Pruijssers AJ, George AS, Schäfer A, Leist SR, Gralinksi LE, Dinnon KH, Yount
BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez
DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D,
Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR,
Sheahan TP. 2020. Remdesivir Inhibits SARS-CoV-2 in human lung cells and
chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell
Rep 32:107940. https://doi.org/10.1016/j.celrep.2020.107940.
7. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC,
Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke
MO, Baric RS, Denison MR. 2018. Coronavirus susceptibility to the antiviral
remdesivir (GS-5734) is mediated by the viral polymerase and the proof-
reading exoribonuclease. mBio 9:e00221-18. https://doi.org/10.1128/
mBio.00221-18.
8. Wan Y, Shang J, Graham R, Baric RS, Li F. 2020. Receptor recognition by
the novel coronavirus from Wuhan: an analysis based on decade-long
structural studies of SARS coronavirus. J Virol 94:e00127-20. https://doi
.org/10.1128/JVI.00127-20.
9. Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, McCune
BT, Fox JM, Chen RE, Alsoussi WB, Turner JS, Schmitz AJ, Lei T, Shrihari S,
Keeler SP, Fremont DH, Greco S, McCray PB, Perlman S, Holtzman MJ,
Ellebedy AH, Diamond MS. 2020. A SARS-CoV-2 infection model in mice
demonstrates protection by neutralizing antibodies. Cell 182:744–753.e4.
https://doi.org/10.1016/j.cell.2020.06.011.
10. Sun S-H, Chen Q, Gu H-J, Yang G, Wang Y-X, Huang X-Y, Liu S-S, Zhang N-
N, Li X-F, Xiong R, Guo Y, Deng Y-Q, Huang W-J, Liu Q, Liu Q-M, Shen Y-L,
Zhou Y, Yang X, Zhao T-Y, Fan C-F, Zhou Y-S, Qin C-F, Wang Y-C. 2020. A
mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host
Microbe 28:124–133.e4. https://doi.org/10.1016/j.chom.2020.05.020.
11. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. 2008. Severe
acute respiratory syndrome coronavirus infection causes neuronal death
in the absence of encephalitis in mice transgenic for human ACE2. J Virol
82:7264–7275. https://doi.org/10.1128/JVI.00737-08.
12. Israelow B, Song E, Mao T, Lu P, Meir A, Liu F, Alfajaro MM, Wei J, Dong H,
Homer RJ, Ring A, Wilen CB, Iwasaki A. 2020. Mouse model of SARS-CoV-2
reveals inflammatory role of type I interferon signaling. J Exp Med 217:
e20201241. https://doi.org/10.1084/jem.20201241.
13. Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F, Qu Y,
Li F, Lv Q, Wang W, Xue J, Gong S, Liu M, Wang G, Wang S, Song Z, Zhao L,
Liu P, Zhao L, Ye F, Wang H, Zhou W, Zhu N, Zhen W, Yu H, Zhang X, Guo
L, Chen L, Wang C, Wang Y, Wang X, Xiao Y, Sun Q, Liu H, Zhu F, Ma C, Yan
L, Yang M, Han J, Xu W, Tan W, Peng X, Jin Q, Wu G, Qin C. 2020. The path-
ogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583:830–833.
https://doi.org/10.1038/s41586-020-2312-y.
14. Dinnon KH, Leist SR, Schäfer A, Edwards CE, Martinez DR, Montgomery SA,
West A, Yount BL, Hou YJ, Adams LE, Gully KL, Brown AJ, Huang E, Bryant
MD, Choong IC, Glenn JS, Gralinski LE, Sheahan TP, Baric RS. 2020. A mouse-
adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature
586:560–569. https://doi.org/10.1038/s41586-020-2708-8.
15. Leist SR, Dinnon KH, Schäfer A, Tse LV, Okuda K, Hou YJ, West A, Edwards
CE, Sanders W, Fritch EJ, Gully KL, Scobey T, Brown AJ, Sheahan TP,
Moorman NJ, Boucher RC, Gralinski LE, Montgomery SA, Baric RS. 2020. A
mouse-adapted SARS-CoV-2 induces acute lung injury (ALI) and mortality
in standard laboratory mice. Cell 183:1070–1085. https://doi.org/10.1016/
j.cell.2020.09.050.
16. Gu H, Chen Q, Yang G, He L, Fan H, Deng Y-Q, Wang Y, Teng Y, Zhao Z,
Cui Y, Li Y, Li X-F, Li J, Zhang N-N, Yang X, Chen S, Guo Y, Zhao G, Wang X,
Luo D-Y, Wang H, Yang X, Li Y, Han G, He Y, Zhou X, Geng S, Sheng X,
Jiang S, Sun S, Qin C-F, Zhou Y. 2020. Adaptation of SARS-CoV-2 in BALB/c
mice for testing vaccine efficacy. Science 369:1603–1607. https://doi.org/
10.1126/science.abc4730.
17. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L,
Wang X. 2020. Structure of the SARS-CoV-2 spike receptor-binding do-
main bound to the ACE2 receptor. Nature 581:215–220. https://doi.org/
10.1038/s41586-020-2180-5.
18. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F.
2020. Structural basis of receptor recognition by SARS-CoV-2. Nature
581:221–224. https://doi.org/10.1038/s41586-020-2179-y.
Adams et al. ®
March/April 2021 Volume 12 Issue 2 e03149-20 mbio.asm.org 8
19. Hirano N, Fujiwara K, Hino S, Matumoto M. 1974. Replication and pla-
que formation of mouse hepatitis virus (MHV-2) in mouse cell line
DBT culture. Arch Gesamte Virusforsch 44:298–302. https://doi.org/10
.1007/BF01240618.
20. Chen W, Baric RS. 1996. Molecular anatomy of mouse hepatitis virus per-
sistence: coevolution of increased host cell resistance and virus virulence.
J Virol 70:3947–3960. https://doi.org/10.1128/JVI.70.6.3947-3960.1996.
21. Menachery VD, Yount BL, Debbink K, Agnihothram S, Gralinski LE, Plante
JA, Graham RL, Scobey T, Ge X-Y, Donaldson EF, Randell SH, Lanzavecchia
A, Marasco WA, Shi Z-L, Baric RS. 2015. A SARS-like cluster of circulating
bat coronaviruses shows potential for human emergence. Nat Med 21:
1508–1513. https://doi.org/10.1038/nm.3985.
22. Denison MR, Graham RL, Donaldson EF, Eckerle LD, Baric RS. 2011. Coro-
naviruses: an RNA proofreading machine regulates replication fidelity
and diversity. RNA Biol 8:270–279. https://doi.org/10.4161/rna.8.2.15013.
23. Eckerle LD, Lu X, Sperry SM, Choi L, Denison MR. 2007. High fidelity of mu-
rine hepatitis virus replication is decreased in nsp14 exoribonuclease
mutants. J Virol 81:12135–12144. https://doi.org/10.1128/JVI.01296-07.
24. Lam TT-Y, Jia N, Zhang Y-W, Shum MH-H, Jiang J-F, Zhu H-C, Tong Y-G,
Shi Y-X, Ni X-B, Liao Y-S, Li W-J, Jiang B-G, Wei W, Yuan T-T, Zheng K, Cui
X-M, Li J, Pei G-Q, Qiang X, Cheung WY-M, Li L-F, Sun F-F, Qin S, Huang J-
C, Leung GM, Holmes EC, Hu Y-L, Guan Y, Cao W-C. 2020. Identifying
SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 583:
282–285. https://doi.org/10.1038/s41586-020-2169-0.
25. Conceicao C, Thakur N, Human S, Kelly JT, Logan L, Bialy D, Bhat S,
Stevenson-Leggett P, Zagrajek AK, Hollinghurst P, Varga M, Tsirigoti C,
Tully M, Chiu C, Moffat K, Silesian AP, Hammond JA, Maier HJ, Bickerton E,
Shelton H, Dietrich I, Graham SC, Bailey D. 2020. The SARS-CoV-2 spike
protein has a broad tropism for mammalian ACE2 proteins. PLoS Biol 18:
e3001016. https://doi.org/10.1371/journal.pbio.3001016.
26. Li Y, Wang H, Tang X, Fang S, Ma D, Du C, Wang Y, Pan H, Yao W, Zhang R,
Zou X, Zheng J, Xu L, Farzan M, Zhong G. 2020. SARS-CoV-2 and three
related coronaviruses utilize multiple ACE2 orthologs and are potently
blocked by an improved ACE2-Ig. J Virol 94:e01283-20. https://doi.org/10
.1128/JVI.01283-20.
27. Schlottau K, Rissmann M, Graaf A, Schön J, Sehl J, Wylezich C, Höper D,
Mettenleiter TC, Balkema-Buschmann A, Harder T, Grund C, Hoffmann
D, Breithaupt A, Beer M. 2020. SARS-CoV-2 in fruit bats, ferrets, pigs,
and chickens: an experimental transmission study. Lancet Microbe 1:
e218–e225. https://doi.org/10.1016/S2666-5247(20)30089-6.
28. Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun
Z, Zhao Y, Liu P, Liang L, Cui P, Wang J, Zhang X, Guan Y, Tan W, Wu G,
Chen H, Bu Z. 2020. Susceptibility of ferrets, cats, dogs, and other domes-
ticated animals to SARS–coronavirus 2. Science 368:1016–1020. https://
doi.org/10.1126/science.abb7015.
29. Wang J, Shuai L, Wang C, Liu R, He X, Zhang X, Sun Z, Shan D, Ge J, Wang
X, Hua R, Zhong G, Wen Z, Bu Z. 2020. Mouse-adapted SARS-CoV-2 repli-
cates efficiently in the upper and lower respiratory tract of BALB/c and
C57BL/6J mice. Protein Cell 11:776–782. https://doi.org/10.1007/s13238
-020-00767-x.
30. Oude Munnink BB, Sikkema RS, Nieuwenhuijse DF, Molenaar RJ, Munger
E, Molenkamp R, van der Spek A, Tolsma P, Rietveld A, Brouwer M,
Bouwmeester-Vincken N, Harders F, Hakze-van der Honing R, Wegdam-
Blans MCA, Bouwstra RJ, GeurtsvanKessel C, van der Eijk AA, Velkers FC,
Smit LAM, Stegeman A, van der Poel WHM, Koopmans MPG. 2021. Trans-
mission of SARS-CoV-2 on mink farms between humans and mink and
back to humans. Science 371:172–177. https://doi.org/10.1126/science
.abe5901.
31. Cockrell AS, Yount BL, Scobey T, Jensen K, Douglas M, Beall A, Tang X-C,
Marasco WA, Heise MT, Baric RS. 2017. A mouse model for MERS coronavi-
rus-induced acute respiratory distress syndrome. 2. Nat Microbiol 2:1–11.
https://doi.org/10.1038/nmicrobiol.2016.226.
32. Menachery VD, Eisfeld AJ, Schäfer A, Josset L, Sims AC, Proll S, Fan S, Li C,
Neumann G, Tilton SC, Chang J, Gralinski LE, Long C, Green R, Williams
CM, Weiss J, Matzke MM, Webb-Robertson B-J, Schepmoes AA, Shukla AK,
Metz TO, Smith RD, Waters KM, Katze MG, Kawaoka Y, Baric RS. 2014.
Pathogenic influenza viruses and coronaviruses utilize similar and con-
trasting approaches to control interferon-stimulated gene responses.
mBio 5:e01174-14. https://doi.org/10.1128/mBio.01174-14.
33. Sang ER, Tian Y, Gong Y, Miller LC, Sang Y. 2020. Integrate structural anal-
ysis, isoform diversity, and interferon-inductive propensity of ACE2 to
predict SARS-CoV2 susceptibility in vertebrates. Heliyon 6:e04818.
https://doi.org/10.1016/j.heliyon.2020.e04818.
34. Menachery VD, Dinnon KH, Yount BL, McAnarney ET, Gralinski LE, Hale A,
Graham RL, Scobey T, Anthony SJ, Wang L, Graham B, Randell SH, Lipkin
WI, Baric RS. 2019. Trypsin treatment unlocks barrier for zoonotic bat co-
ronavirus infection. J Virol 94:e01774-19. https://doi.org/10.1128/JVI
.01774-19.
35. Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F. 2020. Cell entry
mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117:11727–11734.
https://doi.org/10.1073/pnas.2003138117.
36. Cockrell AS, Peck KM, Yount BL, Agnihothram SS, Scobey T, Curnes NR,
Baric RS, Heise MT. 2014. Mouse dipeptidyl peptidase 4 is not a functional
receptor for Middle East respiratory syndrome coronavirus infection. J
Virol 88:5195–5199. https://doi.org/10.1128/JVI.03764-13.
37. Webb B, Sali A. 2016. Comparative protein structure modeling using
MODELLER. Curr Protoc Bioinformatics 54:5.6.1–5.6.37. https://doi.org/10
.1002/cpbi.3.
38. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH, Kato T,
Lee RE, Yount BL, Mascenik TM, Chen G, Olivier KN, Ghio A, Tse LV, Leist
SR, Gralinski LE, Schäfer A, Dang H, Gilmore R, Nakano S, Sun L, Fulcher
ML, Livraghi-Butrico A, Nicely NI, Cameron M, Cameron C, Kelvin DJ, de
Silva A, Margolis DM, Markmann A, Bartelt L, Zumwalt R, Martinez FJ,
Salvatore SP, Borczuk A, Tata PR, Sontake V, Kimple A, Jaspers I, O'Neal
WK, Randell SH, Boucher RC, Baric RS. 2020. SARS-CoV-2 reverse genetics
reveals a variable infection gradient in the respiratory tract. Cell 182:
429–446.e14. https://doi.org/10.1016/j.cell.2020.05.042.
ACE2 Determinants of Group 2B Coronavirus Infection ®
March/April 2021 Volume 12 Issue 2 e03149-20 mbio.asm.org 9
